Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress

AKCAY, GUVEN

doi:10.5455/medscience.2022.12.262

Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress

Güven AKÇAY (Hitit Üniversitesi Tıp Fakültesi Biyofizik Anabilim Dalı, Çorum, Türkiye)

Medicine Science

3 2

Yıl: 2023 Cilt: 12 Sayı: 1 Sayfa Aralığı: 63 - 69 Metin Dili: İngilizce DOI: 10.5455/medscience.2022.12.262 İndeks Tarihi: 29-05-2023

Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress

Öz:

Schizophrenia is a serious neuropsychiatric disorder that affects 1% of the world's population. It plays an important role in psychiatric symptoms, including major depression and schizophrenia. However, it is also known that one of the main reasons underlying the pathogenesis of schizophrenia is oxidative stress. Transcranial direct current stimulation (tDCS) has recently been a promising method for modifying neuronal membrane stimulation, cognition, and behavioral function. Our aim in this study is to explore the effects of 0.5 mA anodal tDCS stimulation on schizophrenia-like behaviors and oxidative stress in a ketamine-induced schizophrenia model. 30 male Balb/C mice were divided into 3 groups as control, schizophrenia, and schizophrenia+tDCS. The schizophrenia model was created by administering 25mg/kg/day ketamine for 7 days. tDCS treatment was performed by giving 0.5 mA anodal tDCS stimulation for 7 days. On day 14 of the experiment, SCZ-like behaviors were assessed using a novel object recognition test (NOR), open field test (OF), and tail suspension test (TST), and also oxidative stress in hippocampus and prefrontal tissues was estimated. Results showed that locomotor activity, depressive and anxiety-like behaviors of the schizophrenia group increased significantly compared to the control group and decreased after tDCS stimulation (p<0.05). In addition, it was investigated that tDCS stimulation also significantly increased learning that decreased after schizophrenia (p<0.05). All together, it was observed that the total antioxidant capacity of the schizophrenia group decreased while the total oxidant capacity of the schizophrenia group rose in the prefrontal cortex and hippocampus tissues compared to the control group (p<0.05). Otherwise, 0.5 mA anodal tDCS stimulation increased the total antioxidant capacity of the schizophrenia+tDCS group compared to the schizophrenia group, while it decreased total oxidant capacity (p<0.05). Based on our results displayed that 0.5 mA anodal tDCS stimulation for 30 minutes for 7 days reduced schizophrenia-like behaviors and oxidative stress by modulation of N-methyl-D-aspartic acid (NMDA) receptors in the glutamatergic pathway in a ketamine- induced, NMDA antagonist, schizophrenia model.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ishola IO, Ben-Azu B, Adebayo OA, et al. Prevention and reversal of ketamine-induced experimental psychosis in mice by the neuroactive flavonoid, hesperidin: The role of oxidative and cholinergic mechanisms. Brain Res Bull. 2021;177:239-51.
2. Parker EM, Sweet RA. Stereological assessments of neuronal pathology in auditory cortex in schizophrenia. Front Neuroanat. 2017;11:131.
3. Xavier RM, Vorderstrasse A. Genetic basis of positive and negative symptom domains in schizophrenia. Biol Res Nurs. 2017;19:559-75.
4. Cunningham C, Peters K. Aetiology of schizophrenia and implications for nursing practice: a literature review. Issues Ment Health Nurs. 2014;35:732-8.
5. Choi YK, Tarazi FI. Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia. BMB Rep. 2010;43:593-8.
6. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010;122:1-23.
7. Yadav M, Jindal DK, Dhingra MS, et al. Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations. Inflammopharmacology. 2018;26:413-24.
8. Koenig JI, Elmer GI, Shepard PD, et al. Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res. 2005;156:251-61.
9. Chatterjee M, Verma R, Ganguly S, Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology. 2012;63:1161-71.
10. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32:1014-23.
11. Parle M, Sharma K. Biomarkers and causative factors of schizophrenia. Int Res J Pharm. 2013;2013:78-85.
12. Kumar A, Yadav M, Parle M, et al. Potential drug targets and treatment of schizophrenia. Inflammopharmacology. 2017;25:277-92.
13. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63:257-65.
14. Okubo Eneni AE, Ben-Azu B, Mayowa Ajayi A, Oladele Aderibigbe A. Diosmin attenuates schizophrenia-like behavior, oxidative stress, and acetylcholinesterase activity in mice. Drug Metab Pers Ther. 2020;/j/ dmdi.ahead-of-print/dmdi-2020-0119/dmdi-2020-0119.xml.
15. Chatterjee M, Verma P, Maurya R, Palit G. Evaluation of ethanol leaf extract of Ocimum sanctum in experimental models of anxiety and depression. Pharm Biol. 2011;49:477-83.
16. Magalhães PV, Dean O, Andreazza AC, et al. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:Cd008919.
17. Dadheech G, Mishra S, Gautam S, Sharma P. Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian journal of clinical biochemistry : IJCB. 2006;21:34-8..
18. Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress- mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry. 2006;18:119-31.
19. Bošković M, Vovk T, Kores Plesničar B, Grabnar I. Oxidative stress in schizophrenia. Current neuropharmacology. 2011;9:301-12.
20. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:200-6.
21. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids. 2003;25(3- 4):207-18.
22. Mitra S, Natarajan R, Ziedonis D, Fan X. Antioxidant and anti- inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2017;78:1-11.
23. Herz MI, Lamberti JS, Mintz J, et al. A program for relapse prevention in schizophrenia: a controlled study. Arch Gen Psychiatry. 2000;57:277-83.
24. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635-45.
25. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008;60:358-403.
26. Akcay G, BahadırA. The Therapeutic Effects of Non-Invasive Transcranial Direct Current Stimulation (tDCS) in Experimental Models of Stroke. In: Chernopolskı PM, Shapekova NL, Ak B, eds. Research Advancements In Health Scıences. 1 ed. St. Klıment Ohrıdskı Unıversıty Press, 2021:28-49.
27. Akcay G, Derin N. The Effects of tDCS on Depression and Anxiety Disorders Induced by Sub-Chronic Stress. Turk Hij Den Biyol Derg. 2022;79:267-78.
28. Nitsche MA, Cohen LG, Wassermann EM, et al. Transcranial direct current stimulation: State of the art 2008. Brain Stimul. 2008;1:206-23.
29. Cavaleiro C, Martins J, Gonçalves J, Castelo-Branco M. Memory and cognition-related neuroplasticity enhancement by transcranial direct current stimulation in rodents: A Systematic Review. Neural Plast. 2020;2020:4795267.
30. Fraga DB, Réus GZ, Abelaira HM, et al. Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration. Braz J Psychiatry. 2013;35:262-6.
31. Johnston IN, Tan M, Cao J, et al. Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats. Behav Brain Res 2017;334:109-1.
32. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 1985;85:367-70.
33. du Bois TM, Deng C, Han M, Newell KA, Huang X-F. Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. European Neuropsychopharmacology. 2009;19:256-65.
34. Moghaddam AH, Maboudi K, Bavaghar B, Sangdehi SRM, Zare M. Neuroprotective effects of curcumin-loaded nanophytosome on ketamine- induced schizophrenia-like behaviors and oxidative damage in male mice. Neurosci Lett. 2021;765:136249.
35. Akosman MS, Türkmen R, Demirel HH. Investigation of the protective effect of resveratrol in an MK-801-induced mouse model of schizophrenia. Environ Sci Pollut Res Int. 2021;28:65872-84.
36. Smith RC, Md WL, Wang Y, et al. Effects of transcranial direct current stimulation on cognition and symptoms in Chinese patients with schizophrenia⃰. Psychiatry Res 2020;284:112617.
37. Adam O, Psomiades M, Rey R, et al. Frontotemporal Transcranial Direct Current Stimulation Decreases Serum Mature Brain-Derived Neurotrophic Factor in Schizophrenia. Brain Sci. 2021;11.
38. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000;48:627-40.
39. Solberg DK, Refsum H, Andreassen OA, Bentsen H. A five-year follow- up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Acta neuropsychiatrica. 2019;31:202-12.

APA	AKCAY G (2023). Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. , 63 - 69. 10.5455/medscience.2022.12.262
Chicago	AKCAY GUVEN Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. (2023): 63 - 69. 10.5455/medscience.2022.12.262
MLA	AKCAY GUVEN Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. , 2023, ss.63 - 69. 10.5455/medscience.2022.12.262
AMA	AKCAY G Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. . 2023; 63 - 69. 10.5455/medscience.2022.12.262
Vancouver	AKCAY G Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. . 2023; 63 - 69. 10.5455/medscience.2022.12.262
IEEE	AKCAY G "Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress." , ss.63 - 69, 2023. 10.5455/medscience.2022.12.262
ISNAD	AKCAY, GUVEN. "Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress". (2023), 63-69. https://doi.org/10.5455/medscience.2022.12.262

APA	AKCAY G (2023). Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. Medicine Science, 12(1), 63 - 69. 10.5455/medscience.2022.12.262
Chicago	AKCAY GUVEN Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. Medicine Science 12, no.1 (2023): 63 - 69. 10.5455/medscience.2022.12.262
MLA	AKCAY GUVEN Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. Medicine Science, vol.12, no.1, 2023, ss.63 - 69. 10.5455/medscience.2022.12.262
AMA	AKCAY G Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. Medicine Science. 2023; 12(1): 63 - 69. 10.5455/medscience.2022.12.262
Vancouver	AKCAY G Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. Medicine Science. 2023; 12(1): 63 - 69. 10.5455/medscience.2022.12.262
IEEE	AKCAY G "Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress." Medicine Science, 12, ss.63 - 69, 2023. 10.5455/medscience.2022.12.262
ISNAD	AKCAY, GUVEN. "Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress". Medicine Science 12/1 (2023), 63-69. https://doi.org/10.5455/medscience.2022.12.262